Intratio
Quantitative Research
Skip to main content
AI Market Summary
Loading market intelligence...
  • Sign in
    My account
    Logout
AI 90-DAY FORECAST
BEARISH SIGNAL DETECTED
██.█% Sign up free to reveal

Silexion Therapeutics Corp (SLXN) AI Forecast

Our AI detected a significant signal for Silexion Therapeutics Corp. Create a free account and follow it to see the exact price target.

✓ Free account • ✓ 30-day free trial

$SLXN Bearish Signal Full forecast available
Sign Up Free

Silexion Therapeutics Corp (SLXN) Stock Forecast Sept. 5, 2026

Silexion Therapeutics Corp (SLXN) AI Stock Price Forecast & Investment Analysis

Silexion Therapeutics Corp Stock Price Chart and Technical Analysis

Loading chart...

Silexion Therapeutics Corp (SLXN) - Comprehensive Stock Analysis & Investment Research

Deep dive into Silexion Therapeutics Corp's business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Analysis updated on September 5, 2026, 3:09 p.m. (UTC)

Silexion Therapeutics Corp Investment Summary

When evaluating whether Silexion Therapeutics Corp (SLXN) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.

Company Profile

Silexion Therapeutics Corp (SLXN) operates within the Life Sciences sector, specifically in the Biological Products, (No Diagnostic Substances) industry. . With a market capitalization of $2 million, the company is a small-cap stock that may offer higher growth potential but also carries higher volatility.

Financial Performance Analysis

Our comprehensive financial analysis covers Silexion Therapeutics Corp's revenue, profitability metrics, balance sheet strength, and cash flow generation...

AI Price Predictions

Get AI-powered 7-day, 30-day and 90-day price forecasts for Silexion Therapeutics Corp along with confidence scores and detailed analysis...

Investment Considerations

Expert analysis of whether Silexion Therapeutics Corp is suitable for your investment objectives, risk tolerance, and time horizon...

Continue Reading Full Analysis

Get the complete investment breakdown for Silexion Therapeutics Corp

Sign Up Free
Corporate Identity

Silexion Therapeutics Corp (Stock Symbol: SLXN) is a prominent company operating within the Life Sciences sector, with a specific focus on the Biological Products, (No Diagnostic Substances) industry. The company's shares are publicly traded on the Nasdaq exchange.

Leadership & Workforce

Detailed information about Silexion Therapeutics Corp's leadership team, workforce size, and organizational structure...

Market Classification

Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Silexion Therapeutics Corp...

Sector & Industry Analysis

In-depth sector dynamics and industry context for Silexion Therapeutics Corp...

Unlock Full Company Profile

Get complete details about Silexion Therapeutics Corp

Sign Up Free
Revenue & Growth Analysis
Profitability Metrics

Net profit margin, gross margin, and operating margin analysis for Silexion Therapeutics Corp...

Market Valuation

P/E ratio, price-to-book, and valuation multiples for Silexion Therapeutics Corp...

Return Metrics

Return on equity (ROE), return on assets (ROA), and capital efficiency for Silexion Therapeutics Corp...

Unlock Financial Analysis

Get complete financial metrics for Silexion Therapeutics Corp

Sign Up Free
AI ANALYSIS AVAILABLE

Unlock Silexion Therapeutics Corp's AI Price Forecast

Join 10,000+ investors using our 67%+ accurate AI predictions

4,000+ Stocks Analyzed
67%+ Accuracy Rate
Daily Updates
Start 30-Day Free Trial →

✓ 30-day free trial • ✓ Cancel anytime

Strategic Market Position

Silexion Therapeutics Corp strategically competes in the highly dynamic Biological Products, (No Diagnostic Substances) marketplace. As a small-cap company, it represents an emerging market participant with potentially significant growth opportunities. Small-caps often offer greater growth potential as they capture market share and scale their operations, though this comes with higher risk and volatility. Success at this stage can lead to substantial returns for early investors who identify winning business models.

Industry Competitive Landscape

Silexion Therapeutics Corp competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.

Operational Efficiency

The company currently shows negative free cash flow of $-12 million . Negative free cash flow may reflect heavy investment in growth, working capital needs, or operational challenges. This is common for high-growth companies investing aggressively but warrants attention for mature businesses.

Asset Utilization Efficiency

Asset turnover ratio of 0.04x indicates lower asset turnover that may reflect the industry's capital-intensive nature or potentially underutilized assets. Companies with low turnover typically depend on strong margins to generate adequate returns on capital.

Financial Strength & Leverage

Current ratio of 0.94 reflects potential liquidity concerns with current liabilities exceeding current assets. While some businesses operate successfully with negative working capital, this warrants understanding of the specific circumstances.

Silexion Therapeutics Corp (SLXN) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Silexion Therapeutics Corp stock analysis.

Deep dive into Silexion Therapeutics Corp's financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Silexion Therapeutics Corp stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Silexion Therapeutics Corp:

P/B Ratio 46.76x
Market Cap $2M
EPS $678.60
Book Value/Share $0.01
Revenue/Share $0.03
FCF/Share $-2.24
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Silexion Therapeutics Corp converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Silexion Therapeutics Corp: An ROE of -26472.7% indicates room for improvement in shareholder value creation.

ROE -26472.7%
ROA -274.3%
ROIC -3903.7%
Tax Rate -0.2%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Silexion Therapeutics Corp's ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Silexion Therapeutics Corp: A current ratio of 0.94 suggests potential liquidity concerns.

Current Ratio 0.94x
D/E Ratio 95.50x
Financial Leverage 96.50x
Interest Coverage 338.9x
Working Capital -$230K
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Silexion Therapeutics Corp's ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Silexion Therapeutics Corp: Free cash flow of $-12M indicates cash challenges that need attention.

Operating Cash Flow -$11M
Free Cash Flow -$12M
Capital Spending -$1M
FCF/Sales -8020.7%
CapEx/Sales 751.0%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Silexion Therapeutics Corp uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Silexion Therapeutics Corp: An asset turnover of 0.04x suggests room for improvement in asset utilization.

Asset Turnover 0.04x
Fixed Assets Turnover 7.8x
Understanding Financial Statement Data

What these metrics mean: Key figures from Silexion Therapeutics Corp's income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Silexion Therapeutics Corp:

Income Statement
Operating Income -$10M
Net Income -$11M
R&D Expense $7M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 4%
Cash & Short-term Investments 2%
Total Liabilities 4%
Dividend & Shareholder Information
Shares Outstanding 6M
Growth Metrics (YoY)
EPS Growth 183405.4%

Latest Silexion Therapeutics Corp Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Silexion Therapeutics Corp (SLXN) stock price and investment outlook.

📰 Loading...

Where SLXN sits on the market map

Explore the map →

Silexion Therapeutics Corp Competitors & Peer Analysis - Life Sciences Sector

Comparative analysis of Silexion Therapeutics Corp against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
ABOS ██% $230M x 4.0x
ABPO ██% $1M x x
ACOG ██% $207M x 3.9x
ADAPY ██% $8M x x
ADMA ██% $2.17B 12.8x 5.3x
ADPT ██% $3.86B x 27.0x
AGEN ██% $351M 3.8x x
AGTX ██% $800K x x
AIM ██% $7M x 0.9x
ALEC ██% $252M x x
ALGS ██% $39M x 1.2x
ALLO ██% $680M x 1.6x
ALVO ██% $1.90B x x
AMGN ██% $236.37B 27.0x 20.2x
APGE ██% $10.18B x x
APTN ██% $57M x x
APTOF ██% $4M x x
ARGX ██% $65.31B x x
ARMP ██% $217M x x
ARTV ██% $543M x 1.6x
ATRA ██% $92M x x
ATYR ██% $49M x 1.0x
AURA ██% $784M x 2.5x
AUTL ██% $596M x 8.0x
AVXL ██% $266M x 2.1x
BCAB ██% $2M x x
BCDA ██% $16M x 6.0x
BCLI ██% $12M x x
BCRX ██% $2.54B x x
BDTX ██% $122M x 1.3x
BEAM ██% $3.06B x 2.9x
BIIB ██% $32.98B 24.0x 1.8x
BKHA ██% $50M 97.5x x
BNTX ██% $26.06B x x
CABA ██% $588M x 2.8x
CADL ██% $973M x 7.7x
CCCC ██% $462M x 1.9x
CELZ ██% $7M x 0.8x
CERO ██% $790K x x
CGEM ██% $1.42B x 4.4x
CGEN ██% $245M 3.5x 2.4x
CGON ██% $6.59B x 6.4x
CGTX ██% $98M x 3.0x
CHRS ██% $219M x 3.6x
CLDI ██% $3M x 1.1x
CLLS ██% $334M x x
CMPX ██% $427M x 2.6x
COAG ██% $2.07B x 4.6x
CPMV ██% $440K x x
CRDF ██% $84M x 3.2x
CRDL ██% $252M x x
CRIS ██% $3M x 0.7x
CRSP ██% $5.46B x 3.1x
CSBR ██% $73M x 18.6x
CVM ██% $28M x 2.6x
DBVT ██% $861M x 5.4x
DNA ██% $434M x 1.0x
DNLI ██% $3.64B x 4.4x
DTIL ██% $194M x 4.3x
DYAI ██% $20M x x
EDIT ██% $470M x 4.5x
EIKN ██% $588M x 1.3x
ELUT ██% $36M 0.7x 2.3x
ENGN ██% $123M x 0.5x
ENTX ██% $519M x 71.5x
ENZN ██% $67M x 0.4x
ESLA ██% $31M x x
EVAX ██% $28M x x
EXEL ██% $14.69B 17.1x 8.0x
EXOZ ██% $64M x 17.4x
FATE ██% $289M x 1.9x
FDMT ██% $827M x 2.0x
FENC ██% $434M x 10.2x
GILD ██% $185.67B x 15.7x
GLUE ██% $1.18B x 2.4x
GNTA ██% $48M x 3.9x
GPLB ██% $180K x x
GRML ██% $15M x 0.3x
HALO ██% $12.57B 30.4x 87.5x
HUMA ██% $166M x 5.3x
IBRX ██% $8.51B x x
IKT ██% $330M x 2.2x
IMA ██% $55M x 0.4x
IMCR ██% $1.92B x 4.6x
IMTX ██% $1.46B x x
IMVT ██% $8.10B x 11.0x
INAB ██% $12M x 0.6x
INKT ██% $58M x x
INMB ██% $67M x 3.3x
INTS ██% $12M x 1.4x
IOVA ██% $3.98B x 5.4x
IPSC ██% $381M x 1.6x
IVVD ██% $237M x 1.3x
JATT ██% $95M x 0.5x
JSPR ██% $24M x 16.7x
KLRS ██% $93M x 1.6x
KOD ██% $2.22B x 36.4x
KRYS ██% $10.60B 43.9x 7.8x
KYMR ██% $9.82B x 6.5x
KYTX ██% $508M x 3.1x
LCTX ██% $273M x 4.5x
LENZ ██% $187M x 0.9x
LIFE ██% $3.91B x 80.1x
LIMN ██% $5M x 16.6x
LONA ██% $71M x 2.1x
LXEO ██% $384M x 1.6x
MAZE ██% $1.48B x 3.3x
MESO ██% $2.25B x x
MGTX ██% $1.31B 16.6x 6.1x
MGX ██% $44M x 0.4x
MOLN ██% $176M x x
MRNA ██% $58.07B x 8.6x
NBIX ██% $15.81B 22.4x 4.3x
NMRA ██% $256M x 5.7x
NVAX ██% $1.68B x x
OCGN ██% $448M x x
OTLK ██% $162M x x
PALI ██% $363M x 3.0x
PASG ██% $15M x 3.4x
PCVX ██% $8.86B x 3.2x
PHGE ██% $4M x 0.4x
PLUR ██% $18M x x
PLX ██% $214M 11.3x 3.0x
PMCB ██% $5M x 0.2x
PRME ██% $649M x 16.3x
PROK ██% $802M x x
PTHS ██% $91M x x
QGEN ██% $9.39B x 2.5x
QNCX ██% $32M x x
REPL ██% $1.42B x 13.4x
RGEN ██% $9.46B 227.7x 4.5x
RGNX ██% $590M x 8.2x
RLAY ██% $4.05B x 4.5x
RVMD ██% $45.00B x 17.3x
RXRX ██% $1.94B x 2.1x
SABS ██% $313M x 1.5x
SANA ██% $1.15B x 7.5x
SCLX ██% $38M x x
SCNI ██% $1M x 0.2x
SGMO ██% $29M x x
SGMOQ ██% $62M x x
SLDB ██% $1.08B x 2.9x
SLXN ██% $2M x 46.8x
SNTI ██% $10M x x
SRRK ██% $6.73B x 26.5x
SRZN ██% $268M x x
STRO ██% $333M x x
TARA ██% $225M x 1.4x
TARS ██% $3.93B x 11.3x
TCRX ██% $48M x 0.7x
TECH ██% $11.31B 62.2x 5.4x
TECX ██% $591M x 2.6x
TIL ██% $52M x 0.5x
TNYA ██% $155M x 2.2x
TSHA ██% $1.82B x 4.7x
TVGN ██% $48M x x
TWST ██% $7.82B x 17.5x
VACH ██% $541M 80.4x x
VALN ██% $621M x x
VCEL ██% $2.07B 85.4x 5.6x
VIR ██% $1.92B x 2.0x
VISK ██% $69M x 0.4x
VIVS ██% $4M x x
VOR ██% $1.28B 2.0x x
VXRT ██% $121M 3.2x 1.5x
VYGR ██% $211M x 1.4x
WINT ██% $10K x x
XFOR ██% $388M x 2.5x
ZEOX ██% $9M x 13.1x
ZIVO ██% $14M x x
ZURA ██% $582M x 3.0x
Reveal all forecasts See exact % predictions for all competitors
Sign up free

Frequently Asked Questions - Silexion Therapeutics Corp Stock Forecast

How accurate are Silexion Therapeutics Corp stock predictions?

Our AI model shows a -14% Spearman correlation coefficient for SLXN predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Silexion Therapeutics Corp stock price forecasts?

Our analysis considers Silexion Therapeutics Corp's financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Silexion Therapeutics Corp a good investment in 2026?

Based on our AI analysis, Silexion Therapeutics Corp shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Silexion Therapeutics Corp forecasts updated?

Silexion Therapeutics Corp stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want a simpler view of Silexion Therapeutics Corp?

View simplified analysis on AI Stock Finder →

My Portfolio

Investment Dashboard

Loading your portfolio...